Liu Mei T
Ment Health Clin. 2021 Nov 8;11(6):347-357. doi: 10.9740/mhc.2021.11.347. eCollection 2021 Nov.
Stimulant use disorder (SUD) is a public health problem in the United States that is associated with increased morbidity and mortality. Psychosocial interventions, such as cognitive behavioral therapy and contingency management, are the main treatment modality for SUDs and no pharmacotherapy is currently FDA approved for this indication. Although some medications show promising data for the treatment of SUD, the evidence remains inconsistent, and the clinical application is limited due to the heterogenicity of the population and the lack of studies in patients with various comorbidities. Selection of pharmacotherapy treatment for methamphetamine intoxication, persistent methamphetamine-associated psychosis with methamphetamine use disorder, and cocaine use disorder in patients with co-occurring OUD are discussed in 3 patient cases.
兴奋剂使用障碍(SUD)在美国是一个公共卫生问题,与发病率和死亡率增加相关。心理社会干预措施,如认知行为疗法和应急管理,是SUD的主要治疗方式,目前尚无药物疗法获美国食品药品监督管理局(FDA)批准用于此适应症。尽管一些药物在SUD治疗方面显示出有前景的数据,但证据仍然不一致,并且由于人群的异质性以及缺乏针对各种合并症患者的研究,临床应用受到限制。在3个患者病例中讨论了对甲基苯丙胺中毒、伴有甲基苯丙胺使用障碍的持续性甲基苯丙胺相关精神病以及同时患有阿片类物质使用障碍(OUD)患者的可卡因使用障碍的药物治疗选择。